Navigating AKT Inhibitor-Associated Adverse Events in HR+/HER2- Advanced Breast Cancer
Alexandria May, PharmD, BCPS
Adam Brufsky, MD, PhD
Choosing Between Neoadjuvant and Perioperative Strategies in NSCLC
Steve Jackson, PharmD
Raghava Reddy Induru, MD
Managing AKT Inhibitor-Associated AEs in HR+/HER2- Advanced Breast Cancer
Charles Turck, PharmD, BCPS, BCCCP
Neil M. Iyengar, MD
Sarah H. Donahue, MPH, NP
Choosing the Right ARPI in Metastatic Castration-Sensitive Prostate Cancer
Brian P. McDonough, MD, FAAFP
Bilal Siddiqui, MD
Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
Joseph Kim, MD, MPH, MBA, FACHE
Samir Dalia, MD
Christopher Jurief
Epic Aura for CRC Screening: A Real-World Perspective
Natalia Usoltseva MD, FACP, MHA
Improving CRC Screening Conversations in Primary Care
Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
Petros Grivas, MD, PhD
HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era
Barbara O'Brien, MD
Nadia Harbeck, MD, PhD
EGFR-Mutated NSCLC With Brain Metastases: Navigating ADC Treatment Decisions
Benjamin Levy, MD
Melin Khandekar, MD, PhD
Getting Biomarker Testing Right in Non-Small Cell Lung Cancer Care
Real-World Cases in Squamous Cell Carcinoma of the Anal Canal Care
Madison Conces, MD
Midhun Malla, MD
ctDNA-Guided Adjuvant Atezolizumab in MIBC: IMvigor011 Insights
Guru P. Sonpavde, MD
Streamlining Colorectal Cancer Screening in OB/GYN Care
Jemel Bingham, MD
Preventing Colorectal Cancer with Smart Screening
Harish Gagneja, MD
Adherence to OB/GYN-Ordered CRC Screening: Real-World Insights
Mallik Greene, PhD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.